BioAtla Appoints New CEO, CMO, and Directors
Ticker: BCAB · Form: 8-K · Filed: Mar 14, 2025 · CIK: 1826892
Sentiment: neutral
Topics: leadership-change, executive-appointment, board-of-directors
TL;DR
BioAtla gets a new CEO (Dr. Short) and CMO (Dr. Burger), both joining the board. Big leadership shakeup.
AI Summary
BioAtla, Inc. announced on March 11, 2025, changes in its executive and director roles. Dr. Jay L. Short has been appointed as Chief Executive Officer and President, and also elected to the Board of Directors. Additionally, Dr. Scott R. Burger has been appointed as Chief Medical Officer and elected to the Board of Directors. These appointments are effective immediately.
Why It Matters
The appointment of a new CEO and CMO, along with their election to the board, signals a potential shift in leadership strategy and operational focus for BioAtla, Inc.
Risk Assessment
Risk Level: medium — Changes in key executive and board positions can introduce uncertainty regarding future strategy and operational execution.
Key Players & Entities
- BioAtla, Inc. (company) — Registrant
- Dr. Jay L. Short (person) — Appointed CEO, President, and Director
- Dr. Scott R. Burger (person) — Appointed CMO and Director
- March 11, 2025 (date) — Effective date of appointments
FAQ
Who has been appointed as the new Chief Executive Officer of BioAtla, Inc.?
Dr. Jay L. Short has been appointed as the new Chief Executive Officer and President of BioAtla, Inc.
When were these executive and director changes effective?
The changes were effective as of March 11, 2025.
Has Dr. Scott R. Burger taken on any new roles at BioAtla, Inc.?
Yes, Dr. Scott R. Burger has been appointed as Chief Medical Officer and elected to the Board of Directors.
What is BioAtla, Inc.'s principal executive office address?
BioAtla, Inc.'s principal executive offices are located at 11085 Torreyana Road, San Diego, California, 92121.
What is the Commission File Number for BioAtla, Inc.?
The Commission File Number for BioAtla, Inc. is 001-39787.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 14, 2025 by Dr. Jay L. Short regarding BioAtla, Inc. (BCAB).